Thermo Fisher Scientific Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Marc N. Casper
- Full Time Employees
- 125,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 168 Third Avenue Waltham MA United States of America 02451
- IPO Date
- Mar 17, 1980
- CIK
- 0000097745
- Website
- thermofisher.com
- Similar Companies
- Business
- Thermo Fisher Scientific Inc. (NYSE: TMO) provides analytical instruments, equipment, software, services, consumables, and reagents for research, analysis, discovery, and diagnostics worldwide. The company offers products including mass spectrometry systems, chromatography instruments, genetic analysis tools, bioprocessing equipment, clinical diagnostics assays, laboratory automation solutions, and electron microscopy technologies; its key brands encompass Thermo Scientific, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon. Headquartered in Waltham, Massachusetts, Thermo Fisher was originally founded in 1902 through the merger of Fisher Scientific and Thermo Electron in 2006, and operates in over 70 countries serving pharmaceutical, biotechnology, academic, government, and healthcare customers across life sciences, analytical technologies, specialty diagnostics, and laboratory products segments. Recently, the company expanded its capabilities through the acquisition of Olink Holding AB in 2024 to bolster proteomics offerings, launched the new Orbitrap Astral mass spectrometer in late 2024 for high-throughput proteomics, and formed strategic partnerships including a multi-year collaboration with AstraZeneca to advance biomarker discovery; in 2025, Thermo Fisher announced expansions in gene editing technologies and sustainable manufacturing initiatives amid ongoing supply chain optimizations.
Acumen Wealth Advisors LLC Sells 2,166 Shares of Thermo Fisher Scientific Inc. $TMO
ImmuPharma picks Thermo Fisher to manufacture diabetes drug candidate
Andra AP fonden Purchases 53,990 Shares of Thermo Fisher Scientific Inc. $TMO
Exploring Analyst Estimates for Thermo Fisher (TMO) Q2 Earnings, Beyond Revenue and EPS
AIA Group Ltd Cuts Stock Holdings in Thermo Fisher Scientific Inc. $TMO
Thermo Fisher Set to Report Q2 Earnings: What's in the Cards?
TMO Fairly Valued by DCF at $478
Thermo Fisher Scientific Announces Quarterly Dividend
Thermo Fisher Q2 Preview: Buy Before The Recovery
Thermo Fisher Scientific Receives First FBI Approval for Rapid DNA Crime Scene Profiles Eligible for National CODIS Searches
Arcturus Picks Thermo Fisher To Support Cystic Fibrosis Therapy
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, July 23, 2026
genedrive shares climb 8% on Thermo Fisher pharmacogenetic testing deal
Thermo Fisher Scientific Showcases New Capabilities Across Manufacturing, Clinical Development and AI-Enabled Research at BIO International 2026
West Pharma names former Thermo Fisher executive Lagarde as CEO
Thermo Fisher Scientific Expands Orbitrap Innovation Across Research, Biopharma and Applied Testing at ASMS 2026
Thermo Fisher (TMO) Surges 6.8%: Is This an Indication of Further Gains?
Thermo Fisher Scientific Inc (TMO) Stock Up 6.8% and Still Undervalued -- GF Score: 83/100
Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
TMO Fairly Valued by DCF at $478